GSK Singapore announced that Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), has been approved for treatment in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and hypereosinophilic syndrome (HES).

Eosinophil-driven diseases are inflammatory conditions associated with elevated levels of eosinophils, a type of white blood cell. CRSwNP is a condition in which patients develop soft tissue growths called nasal polyps which can cause chronic symptoms such as nasal obstruction, loss of smell and discharge.

Raakhi Sippy, Vice President and General Manager – GSK Singapore, said: "These approvals mark a significant chapter for patients in Singapore who are burdened by eosinophilic-driven diseases. To further the impact and help more patients, we are committed to exploring the role of IL-5 inhibition in eosinophil-driven diseases."